Montanova Capital LLC Buys 600,000 Shares of Whitehawk Therapeutics, Inc. $WHWK

Montanova Capital LLC increased its stake in shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) by 16.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 4,300,000 shares of the company’s stock after buying an additional 600,000 shares during the period. Montanova Capital LLC owned 0.08% of Whitehawk Therapeutics worth $19,694,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of WHWK. Orbimed Advisors LLC bought a new position in Whitehawk Therapeutics in the 3rd quarter valued at about $7,915,000. Acuta Capital Partners LLC bought a new stake in shares of Whitehawk Therapeutics during the third quarter worth approximately $6,480,000. KVP Capital Advisors LP bought a new stake in shares of Whitehawk Therapeutics during the fourth quarter worth approximately $5,242,000. Yu Fan acquired a new position in shares of Whitehawk Therapeutics in the third quarter valued at approximately $3,933,000. Finally, BlackRock Inc. acquired a new position in shares of Whitehawk Therapeutics in the second quarter valued at approximately $8,807,000. Institutional investors own 52.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Weiss Ratings cut Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, June 5th. Wall Street Zen raised Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Oppenheimer reiterated an “outperform” rating and set a $7.00 price objective on shares of Whitehawk Therapeutics in a research report on Friday, May 8th. B. Riley Financial began coverage on Whitehawk Therapeutics in a report on Thursday, June 25th. They set a “buy” rating and a $10.00 target price for the company. Finally, Leerink Partners initiated coverage on shares of Whitehawk Therapeutics in a research report on Monday, July 13th. They issued an “outperform” rating and a $9.00 target price for the company. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Whitehawk Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $8.20.

Whitehawk Therapeutics Trading Down 1.7%

Shares of WHWK opened at $4.54 on Tuesday. Whitehawk Therapeutics, Inc. has a 12 month low of $1.76 and a 12 month high of $5.49. The firm’s 50 day moving average is $4.27 and its 200-day moving average is $4.01. The stock has a market capitalization of $258.83 million, a PE ratio of -4.05 and a beta of 0.76.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. Equities research analysts predict that Whitehawk Therapeutics, Inc. will post -1.1 earnings per share for the current fiscal year.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.